IL17A and myeloid sarcoma: On the contrary, both TH1 (CD4+/IFNγ+) (median: HC = 0.01%; MS = 0.1%; p < 0.0001) and TH17 (CD4+/IL-17+) (median: HC = 0.0%; MS = 0.3%; p < 0.0001) T lymphocytes were significantly increased in MS compared to HC.